Bayer: Lymphoma, Non-Hodgkin trials
The registry lists 15 Lymphoma, Non-Hodgkin studies with Bayer as lead sponsor. 0 are open to participants now and 4 have results posted.
Phase 1 6Phase 2 4Phase 3 4No phase 2(a study in two phases counts in both)
Studies
Open to participants first, then studies with results posted, then the rest; newest registration first within each.
- Study of Copanlisib in Combination With Standard Immunochemotherapy in Relapsed Indolent Non-Hodgkin's Lymphoma (iNHL)TerminatedNCT02626455Phase 3Results posted
- Phase III Copanlisib in Rituximab-refractory iNHLCompletedNCT02369016Phase 3Results posted
- Copanlisib and Rituximab in Relapsed Indolent B-cell Non-Hodgkin's Lymphoma (iNHL)CompletedNCT02367040Phase 3Results posted
- Open-label, Uncontrolled Phase II Trial of Intravenous PI3K Inhibitor BAY80-6946 in Patients With Relapsed, Indolent or Aggressive Non-Hodgkin's LymphomasCompletedNCT01660451Phase 2Results posted
- Copanlisib Chinese PK StudyCompletedNCT03498430Phase 1
- First-in-human Study of ATR Inhibitor BAY1895344 in Patients With Advanced Solid Tumors and LymphomasCompletedNCT03188965Phase 1
- Safety and Tolerability of BAY1862864 Injection in Subjects With Relapsed or Refractory CD22-positive Non-Hodgkin's LymphomaCompletedNCT02581878Phase 1
- Japanese Phase Ib/II Copanlisib in Relapsed, Indolent B-cell NHLCompletedNCT02342665Phase 1/2
- COPANLISIB (BAY80-6946) Drug-drug Interaction and Cardiovascular Safety Study in Advanced Solid Tumor and Non-Hodgkin's Lymphoma PatientsCompletedNCT02253420Phase 1
- Copanlisib Pharmacodynamic StudyCompletedNCT02155582Phase 1
- Zevalin Post-marketing Surveillance for Adequateness of Image Interpretation Criteria in JapanCompletedNCT01479387
- A Prospective Observational Study to Evaluate the Quality of Life and the Costs in a Real Life Setting in Patients Who Are Treated With 90Y-ZevalinCompletedNCT01164696
- Study for Evaluation of Efficacy and Safety of SH L 749 to Indolent B-cell Non-Hodgkin's LymphomaCompletedNCT00220285Phase 2
- Treatment With [90]Y-Ibritumomab Tiuxetan Versus no Treatment in Patients With Follicular Non Hodgkin Lymphoma (Stage III or IV) Having Achieved a Partial or Complete Remission After First Line ChemotherapyCompletedNCT00185393Phase 3
- Evaluation of Bay 59-8862 in Patients With Aggressive, Refractory Non-Hodgkin's LymphomaCompletedNCT00044551Phase 2